Morgan Stanley’s Neurotrope, Inc. Common NTRP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-2,436
| Closed | -$3K | – | 7242 |
|
|
2020
Q3 | $3K | Hold |
2,436
| – | – | ﹤0.01% | 6547 |
|
|
2020
Q2 | $3K | Hold |
2,436
| – | – | ﹤0.01% | 6418 |
|
|
2020
Q1 | $2K | Sell |
2,436
-1,234
| -34% | -$1.35K | ﹤0.01% | 6431 |
|
|
2019
Q4 | $4K | Sell |
3,670
-9,365
| -72% | -$7.3K | ﹤0.01% | 6443 |
|
|
2019
Q3 | $11K | Sell |
13,035
-7,367
| -36% | -$33.8K | ﹤0.01% | 6183 |
|
|
2019
Q2 | $164K | Buy |
20,402
+6,490
| +47% | +$43.6K | ﹤0.01% | 5111 |
|
|
2019
Q1 | $76K | Buy |
13,912
+13,872
| +34,680% | +$59.6K | ﹤0.01% | 5507 |
|
|
2018
Q4 | $0 | Sell |
40
-334
| -89% | -$2.02K | ﹤0.01% | 6820 |
|
|
2018
Q3 | $3K | Buy |
+374
| New | +$3.58K | ﹤0.01% | 6535 |
|
|
2018
Q2 | – | Sell |
-9
| Closed | – | – | 6807 |
|
|
2018
Q1 | $0 | Buy |
+9
| New | +$71 | ﹤0.01% | 6770 |
|
|
2017
Q3 | – | Sell |
-5,825
| Closed | -$55K | – | 6665 |
|
|
2017
Q2 | $55K | Buy |
5,825
+1,750
| +43% | +$18.7K | ﹤0.01% | 5827 |
|
|
2017
Q1 | $78K | Buy |
+4,075
| New | +$77.2K | ﹤0.01% | 5694 |
|
Other funds holding NTRP
Morgan Stanley's NTRP Position: Q4 2020 in Review
Morgan Stanley sold out of Neurotrope, Inc. Common (NTRP) in Q4 2020, closing a stake of 2,436 shares — an estimated $3K sold.
Morgan Stanley first reported a position in NTRP in Q1 2017 and held it in 12 quarters. The position peaked at $164K in Q2 2019. 1 fund tracked by Wall St. Rank holds NTRP as of Q4 2020.
- Morgan Stanley reported no remaining Neurotrope, Inc. Common position as of Q4 2020 after selling out during the quarter.
- Morgan Stanley sold 2,436 Neurotrope, Inc. Common shares in Q4 2020, an estimated $3K.
- Morgan Stanley first reported a position in Neurotrope, Inc. Common in Q1 2017 and held it in 12 quarters.
- Morgan Stanley's Neurotrope, Inc. Common position peaked at $164K in Q2 2019.
- 1 fund tracked by Wall St. Rank held Neurotrope, Inc. Common as of Q4 2020.
Based on Morgan Stanley's 13F filing for Q4 2020, filed 16 Feb 2021.